Overview

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Status:
RECRUITING
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Herein, a multicenter randomized controlled trial (RCT) has been designed to explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia.
Phase:
NA
Details
Lead Sponsor:
General Hospital of Shenyang Military Region
Treatments:
18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate
essential 303 forte
Glutathione
Liver Transplantation
Methylprednisolone
polyene phosphatidylcholine
Silymarin
Ursodeoxycholic Acid